Basic Information
| LncRNA/CircRNA Name | PEG10 |
| Synonyms | PEG10, EDR, HB-1, MEF3L, Mar2, Mart2, RGAG3, RTL2, SIRH1 |
| Region | GRCh38_7:94656325-94669695 |
| Ensemble | ENSG00000242265 |
| Refseq | NA |
| Regulatory Mechanism | Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Information of Cancer
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, Luciferase reporter assay, Western blot |
| Sample | bladder tissues, cell lines (HUC4449, RT4, 5637, HT1197, T24) |
| Expression Pattern | up-regulated |
| Function Description | We found the abnormal expression of PEG10, miR-134 and LRP6 in urinary bladder tissues and bladder cancer cell lines. PEG10 overexpression promoted viability, migration and invasion of T24 and HT1197 cells as well as facilitated tumor growth. |
| Pubmed ID | 30953817 |
| Year | 2019 |
| Title | lncRNA PEG10 promotes cell survival, invasion and migration by sponging miR-134 in human bladder cancer. |
External Links
| Links for PEG10 | GenBank HGNC Noncode |
| Links for bladder cancer | Omim Cosmic |